Revelation Biosciences Completes Enrollment And Dosing In First Human Phase 1 Study Of Gemini; Top-Line Data To Include Safety, Tolerability, And Biomarkers; Supports Future Development Across Multiple Indications
Portfolio Pulse from Benzinga Newsdesk
Revelation Biosciences has completed enrollment and dosing in its first human Phase 1 study of Gemini. The top-line data will include safety, tolerability, and biomarkers, supporting future development across multiple indications.
June 13, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revelation Biosciences has completed enrollment and dosing in its first human Phase 1 study of Gemini. The top-line data will include safety, tolerability, and biomarkers, supporting future development across multiple indications.
The completion of enrollment and dosing in a Phase 1 study is a significant milestone for any biotech company. The inclusion of safety, tolerability, and biomarker data in the top-line results will provide critical information for future development. This news is likely to have a positive short-term impact on REVB's stock price as it indicates progress in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100